Journals / Glokom Katarakt / 2007 / Cilt: 2 - Sayı: 1

Cataract and glaucoma after intravitreal triamcinolone injection in a child

Çocukta intravitreal triamsinolon enjeksiyonu sonrası katarakt ve glokom birlikteliği

Pages
59–62
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After intravitreal steroid injections, patients should be closely followed with a complete understanding of potential complications.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A fourteen-years-old male boy presented with decreased vision of his left eye.
📊
Key Findings & Data:Two successive intravitreal triamcinolone injections was performed in an other clinic 25 and 16 months before the presentation for a presumed diagnosis of uveitis.
💡
Conclusion & Impact:After intravitreal steroid injections, patients should be closely followed with a complete understanding of potential complications.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ergen · Glokom · Katarakt

Abstract

A fourteen-years-old male boy presented with decreased vision of his left eye. Two successive intravitreal triamcinolone injections was performed in an other clinic 25 and 16 months before the presentation for a presumed diagnosis of uveitis. His visual acuity had decreased to 0.05 OS. On biomicroscopy, posterior subcapsular cataract was present. Intraocular pressure rised to 49 mm Hg OS with a glaucomatous cupping of 0.9 and severe glaucomatous visual field defect. After 15 days with antiglaucomatous therapy, IOP returned to normal levels in the left eye. Cup/ disk area ratio was 0.5 with a slight improvement in visual field. Two months after the initiation of therapy, the recurrence of iridocyclitis attack which could be controlled with medical therapy was determined. After intravitreal steroid injections, patients should be closely followed with a complete understanding of potential complications.

Özet

On dört yaşında erkek hasta sol gözde görmede azalma yakınmasıyla kliniğimize başvurdu. Hastanın sol gözüne başka bir klinikte üveit nedeniyle 25 ve 16 ay önce iki kez intravitreal triamsinolon enjeksiyonu yapılmıştı. Sol gözde görme keskinliği 0.05’e düşmüştü. Biyomikroskopik incelemede arka subkapsüler katarakt saptandı. Sol gözde göz içi basıncı (GİB) 49 mm Hg idi, 0.9 oranında glokomatöz çukurlaşma ve ağır glokomatöz görme alanı hasarı mevcuttu. Antiglokomatöz tedavinin 15. gününde; GİB sol gözde normal seviyelere geriledi. Çukur/disk oranı 0.5 idi ve görme alanında hafif iyileşme vardı. Tedavi başlangıcının 2. ayında hastada iridosiklit atağı tekrarladı ancak medikal tedavi ile kontrol altına alındı. İntravitreal steroid enjeksiyonlarından sonra gelişebilecek potansiyel komplikasyonlar açısından hastalar yakından takip edilmelidir.

🔖

Cite This Article

ERDURMUŞ, M., AYDIN, B., HEPŞEN, İ. F. (2007). Cataract and glaucoma after intravitreal triamcinolone injection in a child. Glokom Katarakt, Cilt: 2 - Sayı: 1, 59–62. https://ajindex.com/articles/226901

References (12)

  1. Danis RP, Ciulla TA, Pratt LM et al.: Intravitreal triamcinolone ace- tonide in exudative age-related macular degeneration. Retina. 2000;20:244-250.
  2. Jonas JB, Kreissig I, Hugger P et al.: Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003;87:462-468.
  3. Gillies MC, Simpson JM, Billson FAet al.: Safety of an intravitreal injection of triamcinolone: results from a randomized clinical tri­ al, Arch Ophthalmol. 2004;122:336-340.
  4. Challa JK, Gillies MC, Penfold PL et al.: Exudative macular dege­ neration and intravitreal triamcinolone 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277-281.
  5. Gillies MC, Simpson JM, Luo W et al.: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for ne- ovascular age-related macular degeneration one-year results. Arch Ophthalmol. 2003;121:667-673.
  6. Cekic O, Chang S, Tseng JJ et al.: Cataract progression af­ ter intravitreal triamcinolone injection. Am J Ophthalmol. 2005;139:993-998.
  7. Spaide RF, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolo­ ne acetonide for choroidal neovascularization. Ophthalmology. 2005;112:301-304. Jonas JB: Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases. Acta Opht­ halmol Scand. 2005;83:645-63.
  8. Smithen LM, Ober MD, Maranan L et al.: Intravitreal triamci­ nolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740-743.
  9. Jonas JB, Degenring RF, Kreissig I et al.: Intraocular pressure ele­ vation after intravitreal triamcinolone acetonide injection. Opht­ halmology. 2005;112:593-598.
  10. Katz LJ, Spaeth GL, Cantor LB et al.: Reversible optic disk cupping and visual field improvement in adults with glaucoma. Am J Oph­ thalmol. 1989;107:485-492.
  11. Wu SC, Huang SC, Kuo CL et al.: Reversal of optic disc cupping after trabeculotomy in primary congenital glaucoma. Can J Oph­ thalmol. 2002;37:337-341.
  12. Wax MB, Ridley ME, Magargal LE.: Reversal of retinal and optic disc ischemia in a patient with sickle cell trait and glaucoma se­ condary to traumatic hyphema. Ophthalmology. 1982;89:845- 851.